NeuroSense Makes Significant Strides in ALS Treatment with Positive Phase 2b Trial Results.

In a pivotal development for the treatment of Amyotrophic Lateral Sclerosis (ALS), NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive results from its Phase 2b PARADIGM trial. The company's lead drug candidate, PrimeC, demonstrated substantial clinical efficacy, marking a significant milestone in the battle against this severe neurodegenerative disease. $NeuroSense Therapeutics(NRSN.US)$